Works matching DE "PEMBROLIZUMAB"

Results: 1264

根治切除不能な局所進行性および転移性尿路上皮癌 (la/mUC) における新規一次治療の選択肢.

Published in:

Nishinihon Journal of Urology, 2025, v. 87, n. 4, p. 190

By:

鑪野秀一;
榎田英樹

Publication type:

Article

Eosinophil‐induced adverse events induced by treatment with programmed cell death 1/ligand 1 inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system.

Published in:

International Journal of Cancer, 2025, v. 157, n. 2, p. 317, doi. 10.1002/ijc.35398

By:

Lyu, Lu;
Bian, Sainan;
Guan, Kai;
Zhao, Bin

Publication type:

Article

Integrated Glucocorticoids and Traditional Chinese Medicine in a Squamous Lung Cancer Patient with Dermatologic Toxicities Related to Pembrolizumab: A Case Report.

Published in:

Clinical, Cosmetic & Investigational Dermatology, 2025, v. 18, p. 899, doi. 10.2147/CCID.S507952

By:

Chen, Yu Yi;
Wu, Tongtong;
Yang, Guowang;
Yu, Jie

Publication type:

Article

Comparación del acceso y disponibilidad de medicamentos biológicos esenciales en Latinoamérica.

Published in:

Revista Contexto, 2024, n. 61, p. 139, doi. 10.18601/01236458.n61.07

By:

RODRÍGUEZ TIBANÁ, LAURA ESTEFANÍA;
VACA GONZÁLEZ, CLAUDIA PATRICIA;
DURÁN, CARLOS

Publication type:

Article

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.

Published in:

World Journal of Urology, 2019, v. 37, n. 1, p. 95, doi. 10.1007/s00345-018-2486-1

By:

Merseburger, Axel S.;
Apolo, Andrea B.;
Chowdhury, Simon;
Hahn, Noah M.;
Galsky, Matthew D.;
Milowsky, Matthew I.;
Petrylak, Daniel;
Powles, Tom;
Quinn, David I.;
Rosenberg, Jonathan E.;
Siefker-Radtke, Arlene;
Sonpavde, Guru;
Sternberg, Cora N.

Publication type:

Article

Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.

Published in:

World Journal of Urology, 2018, v. 36, n. 11, p. 1727, doi. 10.1007/s00345-018-2332-5

By:

Rouanne, Mathieu;
Roumiguié, Mathieu;
Houédé, Nadine;
Masson-Lecomte, Alexandra;
Colin, Pierre;
Pignot, Géraldine;
Larré, Stéphane;
Xylinas, Evanguelos;
Rouprêt, Morgan;
Neuzillet, Yann

Publication type:

Article

Chemotherapy following immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: clinical effectiveness and influence of inflammatory and nutritional factors.

Published in:

Discover Oncology, 2023, v. 14, n. 1, p. 1, doi. 10.1007/s12672-023-00774-4

By:

Sakai, Akihiro;
Ebisumoto, Koji;
Iijima, Hiroaki;
Yamauchi, Mayu;
Teramura, Takanobu;
Yamazaki, Aritomo;
Watanabe, Takane;
Inagi, Toshihide;
Maki, Daisuke;
Okami, Kenji

Publication type:

Article

Case report: a successful treatment with immune checkpoint inhibitors was associated with severe dermatologic toxicities in a patient with double primary malignancies.

Published in:

Discover Oncology, 2023, v. 14, n. 1, p. 1, doi. 10.1007/s12672-023-00749-5

By:

Li, Xi;
Lei, Yi;
Liu, Jiyan;
Lin, Hongyin;
Chen, Kexin;
yin, Fang;
Wang, Chunhui;
Zhang, Hu

Publication type:

Article

Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?

Published in:

NPJ Precision Oncology, 2022, v. 6, n. 1, p. 1, doi. 10.1038/s41698-022-00273-9

By:

Lelliott, Emily J.;
Sheppard, Karen E.;
McArthur, Grant A.

Publication type:

Article

Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types.

Published in:

NPJ Precision Oncology, 2021, v. 5, n. 1, p. 1, doi. 10.1038/s41698-021-00223-x

By:

Wang, Feicheng;
Yang, Shihao;
Palmer, Nathan;
Fox, Kathe;
Kohane, Isaac S.;
Liao, Katherine P.;
Yu, Kun-Hsing;
Kou, S. C.

Publication type:

Article

Accentuating the Positive: Do Trials Give Unrealistic Expectations of Long-Term Survival?

Published in:

2019

By:

Kiely, Belinda E;
Stockler, Martin R

Publication type:

Editorial

A205 PEMBROLIZUMAB ASSOCIATED SCLEROSING CHOLANGITIS RESPONDS TO COMBINATION OF STEROIDS AND MYCOPHENOLIC ACID: A CASE REPORT.

Published in:

2021

By:

Zhao, X;
Huang, R;
Chen, Y;
Deschênes, M

Publication type:

Case Study

Immune checkpoint inhibitors for urothelial carcinoma.

Published in:

Investigative & Clinical Urology, 2018, v. 59, n. 5, p. 285, doi. 10.4111/icu.2018.59.5.285

By:

Hyung Suk Kim;
Ho Kyung Seo

Publication type:

Article

Impressive response on pembrolizumab monotherapy in a patient with metastatic NSCLC and multiple comorbidities: case report.

Published in:

Oncolog-Hematolog, 2023, n. 64, p. 48

By:

Stolojanu, Anca-Alexandra;
Dumitrescu, Elena-Adriana;
Siminiceanu, Crina-Maria;
Gheorghe, Adelina-Silvana;
Ciontea, Loredana-Maria;
Radu, Matei;
Chirea, Irina-Alexandra;
Bălașa, Mihai;
Mihăilă, Raluca-Ioana;
Kajanto, Lidia-Anca;
Stănculeanu, Dana-Lucia

Publication type:

Article

The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?

Published in:

2017

By:

Cummings, Amy L.;
Garon, Edward B.

Publication type:

Editorial

Treatment of malignant melanoma with coxsackievirus A21 (V937): An emerging oncolytic virotherapy.

Published in:

Experimental Dermatology, 2024, v. 33, n. 9, p. 1, doi. 10.1111/exd.15169

By:

Sakunchotpanit, Goranit;
Patil, Mihir K.;
Venkatesh, Kaushik;
Rohan, Thomas Z.;
Cheng, Debby;
Nambudiri, Vinod E.

Publication type:

Article

Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.

Published in:

Experimental Dermatology, 2016, v. 25, n. 7, p. 553, doi. 10.1111/exd.13030

By:

Gulati, Nicholas;
Carvajal, Richard D.;
Postow, Michael A.;
Wolchok, Jedd D.;
Krueger, James G.

Publication type:

Article

Combination treatment of bilateral periocular sebaceous carcinomas with microsatellite instability with neoadjuvant pembrolizumab and Mohs surgery.

Published in:

Australasian Journal of Dermatology, 2022, v. 63, n. 4, p. e345, doi. 10.1111/ajd.13919

By:

Woods, Alexander D.;
Grushchak, Solomiya;
Williams, Kenya M.;
Tan, Alan;
Krunic, Aleksandar L.

Publication type:

Article

Reply to: Eruptive Bowen's disease in a patient on pembrolizumab for Hodgkin's lymphoma.

Published in:

Australasian Journal of Dermatology, 2022, v. 63, n. 2, p. e195, doi. 10.1111/ajd.13798

By:

Cruañes‐Monferrer, Joana;
Martínez‐Díaz, Francisco;
Monte‐Serrano, Juan;
García‐García, Mar;
Giménez Cortés, María Encarnación

Publication type:

Article

Pembrolizumab associated Stevens–Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.

Published in:

Australasian Journal of Dermatology, 2022, v. 63, n. 1, p. e71, doi. 10.1111/ajd.13704

By:

Zhang, Jing;
Zhang, Peng;
Xu, Qiu‐Yun;
Zhu, Yan‐Ting;
Chen, Wen;
Ji, Chao

Publication type:

Article

Eruptive Bowen's Disease in a patient on pembrolizumab for Hodgkin's lymphoma.

Published in:

Australasian Journal of Dermatology, 2021, v. 62, n. 3, p. e435, doi. 10.1111/ajd.13652

By:

Jiang, Kevin W.;
Zhao, Cathy Y.;
Chan, Charles;
Peduto, Monica Y.;
Kailainathan, Gajan;
Cook, David K.

Publication type:

Article

Acute localised exanthematous pustulosis secondary to pembrolizumab.

Published in:

Australasian Journal of Dermatology, 2017, v. 58, n. 4, p. 322, doi. 10.1111/ajd.12594

By:

Wang, Charlie Y;
Khoo, Christine;
McCormack, Chris J;
Xu, Wen;
Pan, Yan

Publication type:

Article

Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.

Published in:

Australasian Journal of Dermatology, 2017, v. 58, n. 3, p. e109, doi. 10.1111/ajd.12488

By:

Parakh, Sagun;
Nguyen, Rebecca;
Opie, Jacinta M;
Andrews, Miles C

Publication type:

Article

Pembrolizumab induced refractory ocular myasthenia gravis: A case report.

Published in:

New Zealand Medical Student Journal, 2021, n. 33, p. 30, doi. 10.57129/zehr3311

By:

Chaolan Zheng;
Dugena, Oliver

Publication type:

Article

Eosinophilia as a predictor of response to immune checkpoint inhibition in patients with metastatic melanoma.

Published in:

New Zealand Medical Student Journal, 2021, n. 32, p. 22, doi. 10.57129/aeyk1627

By:

Bridgman, Tim

Publication type:

Article

Comparison of PD‐L1 immunohistochemistry assays and response to PD‐1/L1 inhibitors in advanced non‐small‐cell lung cancer in clinical practice.

Published in:

Histopathology, 2019, v. 74, n. 2, p. 269, doi. 10.1111/his.13729

By:

Villaruz, Liza C;
Ancevski Hunter, Katerina;
Kurland, Brenda F;
Abberbock, Shira;
Herbst, Cameron;
Dacic, Sanja

Publication type:

Article

Case report: Sustained complete remission with all-oral MEPED therapy in a patient with Hodgkin's disease developing resistance to pembrolizumab.

Published in:

Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1334233

By:

Reuthner, K.;
Aubele, P.;
Menhart, K.;
Rath, P.;
Harrer, D. C.;
Herr, W.;
Hahn, J.;
Vogelhuber, M.;
Heudobler, D.;
Lueke, F.;
Reichle, A.;
Grube, M.

Publication type:

Article

Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials.

Published in:

Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1172969

By:

Yimeng Guo;
Junting Jia;
Zhiying Hao;
Jing Yang

Publication type:

Article

Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.

Published in:: 2017
Publication type:: Correction Notice

Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer.

Published in:

Lung Cancer: Targets & Therapy, 2020, v. 11, p. 53, doi. 10.2147/LCTT.S254146

By:

Noguchi, Susumu;
Suminaga, Keiichiro;
Kaki, Takahiro;
Kawachi, Hiroaki;
Fukao, Akari;
Terashita, Satoshi;
Horikawa, Sadao;
Ikeue, Tatsuyoshi;
Sugita, Takakazu

Publication type:

Article

Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.

Published in:

Lung Cancer: Targets & Therapy, 2017, v. 8, p. 1, doi. 10.2147/LCTT.S105678

By:

Somasundaram, Ashwin;
Burns, Timothy F.

Publication type:

Article

Targeting PD-I/PD-LI in lung cancer: current perspectives.

Published in:

Lung Cancer: Targets & Therapy, 2015, v. 6, p. 55, doi. 10.2147/LCTT.S55176

By:

González-Cao, María;
Karachaliou, Niki;
Viteri, Santiago;
Morales-Espinosa, Daniela;
Teixidó, Cristina;
Ruiz, Jesús Sánchez;
Molina-Vila, Miquel Ángel;
Santarpia, Mariacarmela;
Rosell, Rafael

Publication type:

Article

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for patients with recurrent or metastatic cervical cancer in China.

Published in:

Current Medical Research & Opinion, 2023, v. 39, n. 3, p. 433, doi. 10.1080/03007995.2023.2178081

By:

Zheng, Zhiwei;
Song, Xiaobing;
Qiu, Guodong;
Xu, Siqi;
Cai, Hongfu

Publication type:

Article

Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea.

Published in:

Cancer Research & Treatment, 2024, v. 56, n. 2, p. 681, doi. 10.4143/crt.2023.1042

By:

Lee, Ji Yun;
Kwon, Ji Hyun;
Hur, Joon Young;
Yi, Jun Ho;
Lee, Ji Hyun;
Cho, Hyungwoo;
Do, Young Rok;
Jo, Jae-Cheol;
Kang, Hye Jin;
Koh, Yougil;
Lee, Won Sik;
Lim, Sung Nam;
Yoon, Sang Eun;
Kim, Seok Jin;
Lee, Jeong-Ok

Publication type:

Article

A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer.

Published in:

Cancer Research & Treatment, 2022, v. 54, n. 4, p. 1005, doi. 10.4143/crt.2021.986

By:

Eo Jin Kim;
Yong-Hee Cho;
Dong Ha Kim;
Dae-Hyun Ko;
Eun-Ju Do;
Sang-Yeob Kim;
Yong Man Kim;
Jae Seob Jung;
Yoonmi Kang;
Wonjun Ji;
Myeong Geun Choi;
Jae Cheol Lee;
Jin Kyung Rho;
Chang-Min Choi

Publication type:

Article

Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer.

Published in:

Cancer Research & Treatment, 2022, v. 54, n. 2, p. 458, doi. 10.4143/crt.2021.425

By:

Hyun-Seock Shin;
Juwhan Choi;
Jinhwan Lee;
Sung Yong Lee

Publication type:

Article

Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.

Published in:

Cancer Research & Treatment, 2022, v. 54, n. 2, p. 424, doi. 10.4143/crt.2021.583

By:

Hyojin Kim;
Hyun Jung Kwon;
Eun Sun Kim;
Soohyeon Kwon;
Kyoung Jin Suh;
Se Hyun Kim;
Yu Jung Kim;
Jong Seok Lee;
Jin-Haeng Chung

Publication type:

Article

Engineering a High-Affinity PD-1 Peptide for Optimized Immune Cell-Mediated Tumor Therapy.

Published in:

Cancer Research & Treatment, 2022, v. 54, n. 2, p. 362, doi. 10.4143/crt.2021.424

By:

Yilei Chen;
Hongxing Huang;
Yin Liu;
Zhanghao Wang;
Lili Wang;
Quanxiao Wang;
Yan Zhang;
Hua Wang

Publication type:

Article

Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus-Positive and -Negative Relapsed or Refractory Non-Hodgkin Lymphomas.

Published in:

Cancer Research & Treatment, 2019, v. 51, n. 2, p. 611, doi. 10.4143/crt.2018.191

By:

Seok-Jin Kim;
Jiyeon Hyeon;
Inju Cho;
Young Hyeh Ko;
Won Seog Kim

Publication type:

Article

A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer.

Published in:

Thyroid, 2019, v. 29, n. 11, p. 1615, doi. 10.1089/thy.2019.0086

By:

Chintakuntlawar, Ashish V.;
Yin, Jun;
Foote, Robert L.;
Kasperbauer, Jan L.;
Rivera, Michael;
Asmus, Erik;
Garces, Nina I.;
Janus, Jeffrey R.;
Liu, Minetta;
Ma, Daniel J.;
Moore, Eric J.;
Morris III, John C.;
Neben-Wittich, Michelle;
Price, Daniel L.;
Price, Katharine A.;
Ryder, Mabel;
Van Abel, Kathryn M.;
Hilger, Crystal;
Samb, Eleyna;
Bible, Keith C.

Publication type:

Article

Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma.

Published in:

Thyroid, 2018, v. 28, n. 7, p. 945, doi. 10.1089/thy.2018.0060

By:

Cabanillas, Maria E.;
Busaidy, Naifa L.;
Dadu, Ramona;
Iyer, Priyanka;
Hofmann, Marie Claude;
Ferrarotto, Renata;
Garden, Adam S.;
Skinner, Heath;
Gunn, G. Brandon;
Ahmed, Salmaan;
Williams, Michelle D.;
Grosu, Horiana;
Zafereo, Mark

Publication type:

Article

Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4.

Published in:

Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-40829-2

By:

Kim, Yoo-Na;
Park, Boram;
Kim, Jae Weon;
Kim, Byoung Gie;
Kim, Sang Wun;
Kim, Hee Seung;
Choi, Chel Hun;
Lim, Myong Cheol;
YL Ngoi, Natalie;
SP Tan, David;
Lee, Jung-Yun

Publication type:

Article

High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019.

Published in:

Clinical Epidemiology, 2021, v. 13, p. 1085, doi. 10.2147/CLEP.S332776

By:

Vesteghem, Charles;
Brøndum, Rasmus Froberg;
Falkmer, Ursula G;
Pottegård, Anton;
Poulsen, Laurids Østergaard;
Bøgsted, Martin

Publication type:

Article

Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report.

Published in:

2018

By:

Li, Dongqi;
He, Chuanchun;
Xia, Yaoxiong;
Du, Yaxi;
Zhang, Jing

Publication type:

journal article

Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study.

Published in:

Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01377-2

By:

Spalato-Ceruso, Mariella;
Bouteiller, Fanny;
Guegan, Jean-Philippe;
Toulmonde, Maud;
Bessede, Alban;
Kind, Michèle;
Cousin, Sophie;
Buy, Xavier;
Palussiere, Jean;
Le Loarer, François;
Dadone-Montaudie, Berengere;
Pulido, Marina;
Italiano, Antoine

Publication type:

Article

Integrated proteogenomic characterization of urothelial carcinoma of the bladder.

Published in:

Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01291-7

By:

Xu, Ning;
Yao, Zhenmei;
Shang, Guoguo;
Ye, Dingwei;
Wang, Haixing;
Zhang, Hailiang;
Qu, Yuanyuan;
Xu, Fujiang;
Wang, Yunzhi;
Qin, Zhaoyu;
Zhu, Jiajun;
Zhang, Fan;
Feng, Jinwen;
Tian, Sha;
Liu, Yang;
Zhao, Jianyuan;
Hou, Jun;
Guo, Jianming;
Hou, Yingyong;
Ding, Chen

Publication type:

Article

Levels and in vitro functional effects of circulating anti-hinge antibodies in melanoma patients receiving the immune checkpoint inhibitor pembrolizumab.

Published in:

PLoS ONE, 2023, v. 18, n. 9, p. 1, doi. 10.1371/journal.pone.0290793

By:

Hock, Barry D.;
Goddard, Liping;
MacPherson, Sean A.;
Strother, Matthew;
Gibbs, David;
Pearson, John F.;
McKenzie, Judith L.

Publication type:

Article

Fatal triad of checkpoint inhibitors: Pembrolizumab induced myasthenia gravis with myositis and myocarditis in a patient with thymoma.

Published in:

Neurology Asia, 2023, v. 28, n. 2, p. 439, doi. 10.54029/2023ezm

By:

Seker, Demet;
Yildirim, Ahmet

Publication type:

Article

A Study of Patients with Recurrent or Metastatic Head and Neck Cancer Treated with Pembrolizumab.

Published in:

Tokai Journal of Experimental & Clinical Medicine, 2022, v. 47, n. 3, p. 99

By:

Hiroaki IIJIMA;
Akihiro SAKAI;
Koji EBISUMOTO;
Tomoaki MURAKAMI;
Daisuke MAKI;
Takanobu TERAMURA;
Mayu YAMAUCHI;
Aritomo YAMAZAKI;
Toshihide INAGI;
Kenji OKAMI

Publication type:

Article

Updates on High-Grade Nonmuscle-Invasive Bladder Cancer Clinical Trials.

Published in:

AUANews, 2024, v. 29, n. 12, p. 14

By:

Wald, Gal;
Pietzak, Eugene

Publication type:

Article